Geeta Madathil Govindaraj

Dr. Geeta Madathil Govindaraj

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
KGKalpana George
Kalpana George
GGGeeta Madathil Govindaraj
Geeta Madathil Govindaraj
Enhanced susceptibility to microbes, often resulting in severe, intractable and frequent infections due to usually innocuous organisms at uncommon sites, is the most striking feature in individuals with an inborn error of immunity. In this narrative review, based on the International Union of Immunological Societies’ 2022 (IUIS 2022) Update on phenotypic classification of human inborn errors of immunity, the focus is on commonly encountered Combined Immunodeficiency Disorders (CIDs) with susceptibility to infections. Combined immune deficiency disorders are usually commensurate with survival beyond infancy unlike Severe Combined Immune Deficiency (SCID) and are often associated with clinical features of a syndromic nature. Defective humoral and cellular immune responses result in susceptibility to a broad range of microbial infections. Although disease onset is usually in early childhood, mild defects may present in late childhood or even in adulthood. A precise diagnosis is imperative not only for determining management strategies, but also for providing accurate genetic counseling, including prenatal diagnosis, and also in deciding empiric treatment of infections upfront before investigation reports are available.

21 August 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GGGeeta Madathil Govindaraj
Geeta Madathil Govindaraj
AJAbhinav Jain
Abhinav Jain
GPGeetha Peethambaran
Geetha Peethambaran
RBRahul C. Bhoyar
Rahul C. Bhoyar
SVShamsudheen Karuthedath Vellarikkal
Shamsudheen Karuthedath Vellarikkal
VSVinod Scaria
Vinod Scaria
Hyper-IgD syndrome (HIDS, OMIM #260920) is a rare autosomal recessive autoinflammatory disorder caused by pathogenic variants in the mevalonate kinase (MVK) gene. HIDS has an incidence of 1:50,000 to 1:5,000, and is thought to be prevalent mainly in northern Europe. Here, we report a case series of HIDS from India, which includes ten patients from six families who presented with a wide spectrum of clinical features such as recurrent fever, oral ulcers, rash, arthritis, recurrent diarrhea, hepatosplenomegaly, and high immunoglobulin levels. Using whole exome sequencing (WES) and/or Sanger capillary sequencing, we identified five distinct genetic variants in the MVK gene from nine patients belonging to six families. The variants were classified as pathogenic or likely pathogenic as per the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG-AMP) guidelines for annotation of sequence variants. Over 70% of patients in the present study had two recurrent mutations in MVK gene i.e. a nonsynonymous variant p.V377I, popularly known as the ‘Dutch mutation’, along with a splicing variant c.226+2delT in a compound heterozygous form. Identity by descent analysis in two patients with the recurrent variants identified a 6.7 MB long haplotype suggesting a founder effect in the South Indian population. Our analysis suggests that a limited number of variants account for the majority of the patients with HIDS in South India. This has implications in clinical diagnosis, as well as in the development of cost-effective approaches for genetic diagnosis and screening. To our best knowledge, this is the first and most comprehensive case series of clinically and genetically characterized patients with HIDS from India.

31 March 2010 in Indian Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
GGGeeta Madathil Govindaraj
Geeta Madathil Govindaraj
PGP. Geetha
P. Geetha
VAV. T. Ajithkumar
V. T. Ajithkumar
PKP. Krishnakumar
P. Krishnakumar
KKK. Suresh Kumar
K. Suresh Kumar
LMLulu Mathews
Lulu Mathews

1 January 2007 in Indian Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
GGGeeta Madathil Govindaraj
Geeta Madathil Govindaraj
PKP. Krishnakumar
P. Krishnakumar
LMLulu Mathews
Lulu Mathews

8 September 2021 in Pediatric Allergy, Immunology, and Pulmonology
Verified
Journal Article
Closed access
FDFiji Madona Devassikutty
Fiji Madona Devassikutty
AJAbhinav Jain
Abhinav Jain
AEAthulya Edavazhippurath
Athulya Edavazhippurath
MJMichael Chittettu Joseph
Michael Chittettu Joseph
MPMohammed Manakkattu Thekke Peedikayil
Mohammed Manakkattu Thekke Peedikayil
GGGeeta Madathil Govindaraj
Geeta Madathil Govindaraj
Introduction: The Centers for Disease Control and Prevention (CDC) has listed primary immunodeficiency disorders as being predisposed to severe coronavirus disease 2019 (COVID-19). However, patients affected with X-linked agammaglobulinemia (XLA) have shown contrary results. In this study, we present 2 boys in late adolescence from south India with XLA who were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as a review of cases reported in the literature. Case Presentation: Two patients with XLA had been diagnosed late and were started on regular immunoglobulin prophylaxis only during adolescence. Both of them had developed bronchiectasis, an irreversible suppurative lung disease. However, both patients made an uneventful recovery without the need for artificial ventilation or convalescent plasma. Conclusion: Successful outcomes of patients with XLA and COVID-19, except for delayed recovery, from our experience and from global reports are intriguing and the role of B cell depletion is being studied as well. Further research and clinical experience are necessary to fully elucidate the reasons for these observations.

1 January 2014 in Critical Care
Verified
Journal Article
Open access
PDF file
GGGeeta Madathil Govindaraj
Geeta Madathil Govindaraj
ARArakkal Riyaz
Arakkal Riyaz
Tetanus is still a scourge among the under-privileged populations of the world, and unfortunately remains an important cause of death although a cheap, safe and highly efficacious vaccine is available. The rarity of the disease in some parts of the world results in newly trained physicians being unable to make a clinical diagnosis, and hampers the conduct of adequately powered randomized controlled trials. Several new and experimental pharmacological agents are being used to control the spasms in tetanus, and to combat the autonomic instability that occurs in the disease. New evidence is emerging regarding the use of antibiotics and intrathecal immunoglobulin in tetanus. It is imperative, therefore, that all physicians working in critical care should be aware of the current advances and evidence-based guidelines for management of tetanus in order to achieve the best outcomes, which Rodrigo and colleagues have reviewed in a recent issue of Critical Care.